TCI Wealth Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-509
| Closed | -$12.3K | – | 2496 |
|
|
2023
Q1 | $12.3K | Buy |
509
+109
| +27% | +$1.37K | ﹤0.01% | 961 |
|
|
2022
Q4 | $4.23K | Hold |
400
| – | – | ﹤0.01% | 1639 |
|
|
2022
Q3 | $2K | Hold |
400
| – | – | ﹤0.01% | 2014 |
|
|
2022
Q2 | $2K | Hold |
400
| – | – | ﹤0.01% | 2070 |
|
|
2022
Q1 | $3K | Sell |
400
-690
| -63% | -$4.13K | ﹤0.01% | 1937 |
|
|
2021
Q4 | $6K | Buy |
1,090
+690
| +173% | +$4.38K | ﹤0.01% | 1603 |
|
|
2021
Q3 | $3K | Sell |
400
-464
| -54% | -$2.98K | ﹤0.01% | 2068 |
|
|
2021
Q2 | $7K | Sell |
864
-236
| -21% | -$1.9K | ﹤0.01% | 1260 |
|
|
2021
Q1 | $12K | Buy |
1,100
+100
| +10% | +$1.41K | 0.01% | 788 |
|
|
2020
Q4 | $17K | Hold |
1,000
| – | – | 0.01% | 535 |
|
|
2020
Q3 | $13K | Buy |
1,000
+200
| +25% | +$2.53K | 0.01% | 531 |
|
|
2020
Q2 | $11K | Hold |
800
| – | – | ﹤0.01% | 566 |
|
|
2020
Q1 | $7K | Sell |
800
-200
| -20% | -$2.58K | ﹤0.01% | 653 |
|
|
2019
Q4 | $15K | Buy |
1,000
+200
| +25% | +$1.78K | 0.01% | 623 |
|
|
2019
Q3 | $5K | Buy |
800
+700
| +700% | +$7.08K | ﹤0.01% | 834 |
|
|
2019
Q2 | $1K | Buy |
+100
| New | +$544 | ﹤0.01% | 1357 |
|
Other funds holding PRVB
TCI Wealth Advisors's PRVB Position: Q2 2023 in Review
TCI Wealth Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 509 shares — an estimated $12.3K sold.
TCI Wealth Advisors first reported a position in PRVB in Q2 2019 and held it in 16 quarters. The position peaked at $17K in Q4 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- TCI Wealth Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- TCI Wealth Advisors sold 509 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $12.3K.
- TCI Wealth Advisors first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- TCI Wealth Advisors's Provention Bio, Inc. Common Stock position peaked at $17K in Q4 2020.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.